 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123» |
- | Beovu (brolucizumab-dbll) / Novartis, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Sub-RPE Disease in Neovascular AMD. (Pubmed Central) - Mar 12, 2022
EZ integrity, SHRM, and sub-RPE disease features in eyes with nAMD showed improvement as early as Week 4 of anti-VEGF treatment. EZ integrity measures and SHRM volume were predictors of visual acuity over the first year of treatment.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Recurrent neovascular age-related macular degeneration after discontinuation of VEGF inhibitors managed in a treat and extend regimen. (Pubmed Central) - Mar 12, 2022
It is difficult to predict which patients will have a recurrence and most of these patients do not have symptoms in the early stages of reactivation. Long-term follow-up is important and early detection of recurrent disease can improve the chances for maintained visual function.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Timing of Complete Polypoidal Regression Following Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy. (Pubmed Central) - Mar 12, 2022
Most PCV eyes with complete polypoidal regression at one year already had complete regression within the first 6 months. These findings support consideration of aflibercept for PCV to achieve both anatomical and visual outcomes.
- || Cyramza (ramucirumab) / Eli Lilly, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Vectibix (panitumumab) / Amgen, Takeda
Retrospective data, Review, Journal: The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis. (Pubmed Central) - Mar 11, 2022
These findings support consideration of aflibercept for PCV to achieve both anatomical and visual outcomes. Our study shows that Doublet+Bev has the major probability to provide an improvement of survival in patients with mCRC.
- | Beovu (brolucizumab-dbll) / Novartis, Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Mar 11, 2022
We found a higher effectiveness of brolucizumab therapy compared to aflibercept in patients with nAMD during an observations period lasting 20 weeks. Our observations are significant, although they require further research.
- | Avastin (bevacizumab) / Roche
Preclinical, Journal: In vitro and in ovo experimental study of two anti-VEGF agents used in ophthalmology. (Pubmed Central) - Mar 11, 2022
In both cases, the only notable change was the appearance of a slight vascular coagulation. The viability of the embryos after application was good, they survived more than 24 hours after testing the compounds on the CAM.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Zaltrap (ziv-aflibercept IV) / Sanofi, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Clinical: New #JITC article: Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors https://t.co/9z0C9Oq9Bb @OsamaRahma2 @EladSharonMD (Twitter) - Mar 9, 2022
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal, Real-world evidence: Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes. (Pubmed Central) - Mar 9, 2022
BCVA recovered during 24 months of IVT-AFL treatment in the real-world setting. However, there was a trend toward less improvement compared with the results of randomized controlled trials, likely due in part to undertreatment.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. (Pubmed Central) - Mar 8, 2022
The incidence of lesion reactivation was highest during the first 12 months and decreased thereafter. The incidence was higher in patients with PCV than in those with neovascular AMD, especially after 12 months.
- ||| Vabysmo (faricimab) / Roche
P3 data, Journal, Head-to-Head: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. (Pubmed Central) - Mar 8, 2022
P3
The incidence was higher in patients with PCV than in those with neovascular AMD, especially after 12 months. Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD.
- ||| Vabysmo (faricimab) / Roche
P3 data, Journal: Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. (Pubmed Central) - Mar 8, 2022
P3
Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD. Robust vision gains and anatomical improvements with faricimab were achieved with adjustable dosing up to every 16 weeks, demonstrating the potential for faricimab to extend the durability of treatment for patients with diabetic macular oedema.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept. (Pubmed Central) - Mar 8, 2022
A relatively high proportion of polyp regression was observed in the IVA group (63%) compared with the IVC group (55%) via OCTA. Visual and anatomic outcomes were significantly improved in both IVA and IVC groups, but the results suggest a potentially superior short-term response in the IVA group.
- | Beovu (brolucizumab-dbll) / Novartis, Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Changes in Systemic Levels of Vascular Endothelial Growth Factor After Intravitreal Injection of Aflibercept or Brolucizumab for Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Mar 5, 2022
Visual and anatomic outcomes were significantly improved in both IVA and IVC groups, but the results suggest a potentially superior short-term response in the IVA group. Intravitreal brolucizumab resulted in a sustained reduction of systemic VEGF-A levels until 28 days post-treatment, which raises concerns regarding its safety and long-term effects.
- || LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Biomarker, Clinical, Journal: Proteomic changes of aqueous humor in proliferative diabetic retinopathy patients treated with different intravitreal anti-VEGF agents. (Pubmed Central) - Mar 5, 2022
In summary, we discovered that ALDH3A1 was a previously unreported protein that was related to angiogenesis and was differentially expressed in the three anti-VEGF treatment groups, suggesting that it may be a new target for PDR therapy. The described proteomic changes in the AH of PDR patients treated with different anti-VEGF agents provide novel targets which may explain the heterogeneity of anti-VEGF treatment responses in these patients, providing a robust foundation for future studies of PDR pathogenesis.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Efficacy of a disease management program of a tertiary center and ophthalmologic practitioners for the treatment of neovascular age related macular degeneration. (Pubmed Central) - Mar 4, 2022
Data revealed the efficacy of a DMP for nAMD involving both ophthalmologic practitioners and a tertiary center. Avoiding redundant examinations increased the efficacy of a clinical setting.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept, Conbercept) on autophagy and its effect on neovascularization in RF/6A cells. (Pubmed Central) - Mar 4, 2022
The combination of Conbercept and autophagy inhibitor can significantly inhibit the formation of angiogenesis in vitro. The mechanism of autophagy activation is related to the activation of the p53/DRAM pathway.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Clinical, Journal: Efficacy and safety of Intravitreal Aflibercept Vs Verteporfin Photodynamic Therapy in a Caucasian Population with Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. (Pubmed Central) - Mar 4, 2022
P4
Aflibercept monotherapy in a T&E showed to be effective and safe with a significant median BCVA improvement of 6 letters and a complete occlusion of polypoidal lesions in near 3 quarters of the eyes, at 1 year. As only 22% of the eyes underwent PDT treatment, the benefit of combined treatment for PCV in Caucasian patients could not be definitively elucidated from this study.
- | Avastin (bevacizumab) / Roche
Journal: Effect of long-term anti-VEGF treatment on viability and function of RPE cells. (Pubmed Central) - Mar 3, 2022
As only 22% of the eyes underwent PDT treatment, the benefit of combined treatment for PCV in Caucasian patients could not be definitively elucidated from this study. Long term treatment with anti VEGF may affect viability of RPE cells, and treatment with bevacizumab may have effects on RPE function in long term treatment.
- || Avastin (bevacizumab) / Roche
Retrospective data, Review, Journal: Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis. (Pubmed Central) - Mar 3, 2022
However, this finding is based on indirect evidence through one small trial comparing conbercept with placebo. This does not account for drug-specific differences when assessing anatomic and functional treatment efficacy in variable dosing regimens.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Assessment of choriocapillaris/Sattler and Haller layer changes after intravitreal injection in eyes with neovascular age-related macular degeneration: aflibercept vs ranibizumab. (Pubmed Central) - Mar 3, 2022
Aflibercept treatment has a more pronounced effect on the CC/Sattler layer. Such results may indicate that aflibercept treatment influences choroidal neovascularization, possibly by reducing the capillary permeability associated with active neovascularization in the CC layer.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Retrospective data, Journal: Polypoidal choroidal vasculopathy in pachychoroid: combined treatment with photodynamic therapy and aflibercept. (Pubmed Central) - Mar 3, 2022
The results support the use of a combined therapy with Aflibercept and PDT in PPCV. This treatment would act in synergy, with anti-VEGF controlling exudation and PDT closing the aneurysmal vessel and reducing choroidal congestion.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity. (Pubmed Central) - Mar 3, 2022
Serum VEGF levels are suppressed for at least 8 weeks, and aflibercept could be detected in the systemic circulation at 4 weeks after injection. Clinicians should be cautious about changes in systemic VEGF levels and passage of the agent into systemic circulation after IVA in infants.
- | Journal: The emerging role of the angiopoietin-Tie pathway as therapeutic target for treating retinal diseases. (Pubmed Central) - Mar 3, 2022
Further clinical trials are necessary to define the role of agents targeting Ang/Tie in future clinical practice. Among the investigational drugs targeting the Ang/Tie pathway, faricimab has shown promising results in phase II/III trials and in the near future may represent a viable treatment option for the management of exudative macular diseases.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Journal: Evaluation of the effects of intravitreal aflibercept and ranibizumab on systemic inflammatory and cardiovascular biomarkers in patients with neovascular age-related macular degeneration. (Pubmed Central) - Mar 1, 2022
Also, there was no significant change in fibrinogen, lymphocyte count, MLR, HDL-c, UA, PLR, and platelet count values in both groups. Compared to IVR, IVA treatment had a small but significant effect on systemic inflammatory and cardiovascular biomarkers.
- || LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Journal: Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study. (Pubmed Central) - Mar 1, 2022
Less frequent dispensations and surveillance examinations were observed than in monthly schemes applied in registration trials for IVT anti-VEGF. These results may indicate a lack of systematic monitoring associated with fewer injections and/or clinicians' preference for more flexible and personalized injection schemes than those originally recommended.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron
Reimbursement, Retrospective data, Journal: Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan. (Pubmed Central) - Mar 1, 2022
Eyes receiving aflibercept required less supplementary PRP and SMPL treatment than those receiving ranibizumab. The initial VA influenced the final VA improvements at 24 months, while age and initial CRT were prognostic predictors of 24-month CRT reduction.
- | Avastin (bevacizumab) / Roche
Journal: Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice. (Pubmed Central) - Feb 27, 2022
The initial VA influenced the final VA improvements at 24 months, while age and initial CRT were prognostic predictors of 24-month CRT reduction. Fixed q8 ranibizumab, q8 bevacizumab, q12 aflibercept, or q10 brolucizumab regimens may produce adequate intraocular VEGF inhibition.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial. (Pubmed Central) - Feb 27, 2022
P4
Fixed q8 ranibizumab, q8 bevacizumab, q12 aflibercept, or q10 brolucizumab regimens may produce adequate intraocular VEGF inhibition. EMB does not reduce the number of anti-vascular endothelial growth factor (VEGF) injections, either within or outside of a trial setting, and is associated with worse BCVA than anti-VEGF monotherapy.
- || Avastin (bevacizumab) / Roche, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Clinical, Journal: Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience. (Pubmed Central) - Feb 26, 2022
EMB does not reduce the number of anti-vascular endothelial growth factor (VEGF) injections, either within or outside of a trial setting, and is associated with worse BCVA than anti-VEGF monotherapy. Although no statistically significant differences have been found in TT or PFS, it would be more advisable to use BFIR scheme due to its better results in OS and toxicity profile.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema. (Pubmed Central) - Feb 26, 2022
Although no statistically significant differences have been found in TT or PFS, it would be more advisable to use BFIR scheme due to its better results in OS and toxicity profile. This straightforward and practical TAE regimen using intravitreal aflibercept injections resulted in favorable clinical outcomes with minimal treatment burden for DME at Week 52.
- | Avastin (bevacizumab) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Anti-Vascular Endothelial Growth Factor Drug Conbercept-Loaded Peptide Hydrogel Reduced Angiogenesis in the Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Feb 26, 2022
The In vitro experiments showed that either dose-dependent or the time-dependent incubation with peptide would not decrease the cell viability of HREC, revealing that the peptide was biocompatible. The most important is that co-incubation with HREC obviously reduced the HREC proliferation and tube formation induced by VEGF, ensuring its potential for the treatment efficacy of nAMD.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Preclinical, Journal: VEGF-Trap Modulates Retinal Inflammation in the Murine Oxygen-Induced Retinopathy (OIR) Model. (Pubmed Central) - Feb 26, 2022
VEGF-Trap (Aflibercept, AFL), a recombinant decoy receptor recognizing ligands of both VEGFR-1 and -2, was recently reported to be highly efficient in improving visual acuity and preserving retinal anatomy in individuals affected by diabetic macular edema...We show that AFL administration during the hypoxic period of OIR leads to an increased number of ramified Iba1 microglial cells/macrophages while subsequently limiting the accumulation of these cells in particular retinal layers. Our results suggest that, beyond its well-documented beneficial effects on microvascular regeneration, AFL might exert important modulatory effects on post-ischemic retinal inflammation.
- | Avastin (bevacizumab) / Roche
Journal: Mid-Term Impact of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure. (Pubmed Central) - Feb 26, 2022
Ranibizumab was associated with a higher rate of increase in clinically significant IOP at 6 months (p = 0.03). Our study confirms that anti-VEGF injections constitute a relatively safe treatment regarding their impact on IOP.
- | Beovu (brolucizumab-dbll) / Novartis, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Pricing, Journal: Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases. (Pubmed Central) - Feb 26, 2022
We propose mechanisms for anticipating and facilitating the market introduction of biosimilars, as well as changes to the pricing model in Medicare that can promote use of cost-effective therapies. Reforms such as empowering Medicare to negotiate drug prices may help ensure that introduction of new biologics and biosimilars for AMD will lower spending and increase patient access.
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Real-world evidence: Real-world incidence of endophthalmitis after intravitreal anti-VEGF injection: Common Data Model in ophthalmology. (Pubmed Central) - Feb 25, 2022
The off-label use of bevacizumab accounted for its disproportionately high incidence of endophthalmitis. The OMOP CDM, which includes off-label uses, laboratory data, and a scalable standardized database, could provide a novel strategy to reveal real-world evidence, especially in ophthalmology.
- | Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi, Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration. (Pubmed Central) - Feb 24, 2022
However, the concentration of ziv-aflibercept decreased less than the minimum expected concentration of 8 ng/mL after 60 days at 4 °C and after 30 days at 25.8 °C. The repackaged anti-VEGF drug ziv-aflibercept does not lose stability or efficacy and remains uncontaminated if prepared under sterile conditions and stored at 4 °C for up to 60 days or stored at 25.8 °C for up to 30 days.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron
Review, Journal: Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift? (Pubmed Central) - Feb 24, 2022
In addition, recent randomized trials (PANORAMA and Protocol W) have revealed that early intervention with intravitreal aflibercept in eyes with moderately severe to severe NPDR is associated with significant improvement in DRSS and reduced vision-threatening complications of DR...The cost-benefit ratio is also a challenge. Herein, we look at different aspects of early anti-VEGF application and discuss its pros and cons in the process of treating NPDR.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Yes! I recently saw this with intravitreal Aflibercept (Twitter) - Feb 22, 2022
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Clinical, Journal: The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study. (Pubmed Central) - Feb 22, 2022
Moreover, patients with LTFU had a 13 times higher risk of developing a proliferative DR. Considering the potential disease progress, better strategies should be applied to optimize the functional outcome of patients at risk of reduced adherence.
- | Avastin (bevacizumab) / Roche
Journal: Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. (Pubmed Central) - Feb 19, 2022
Further evidence is required to assess the comparative efficacy of these therapies. Given the limited high-quality comparative efficacy data, choice of therapy must be individualized for each patient and broad therapeutic access for patients is critical to maximize outcomes.
- | Avastin (bevacizumab) / Roche
Journal: Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. (Pubmed Central) - Feb 19, 2022
Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease.
- || LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Clinical, Journal: Efficacy and safety of Aflibercept for the treatment of idiopathic choroidal neovascularization in young patients: the INTUITION study. (Pubmed Central) - Feb 19, 2022
The present analysis shows clinically significant functional and anatomical treatment effect of aflibercept in case of iCNV. The treat-and-extend regimen proposed after the first injection seems adequate to treat the majority of neovessels.
- | Beovu (brolucizumab-dbll) / Novartis
Journal: Bilateral blindness after uneventful brolucizumab injection for macular degeneration. (Pubmed Central) - Feb 19, 2022
We do not recommend performing bilateral brolucizumab injections until more data is available regarding the mechanism of brolucizumab-induced vasculitis. From a clinical point of view, we find it difficult to justify the use of brolucizumab when there are other well-known agents, such as ranibizumab and aflibercept, which have better safety profiles and comparable efficacy.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Network analysis and the impact of Aflibercept on specific mediators of angiogenesis in HUVEC cells. (Pubmed Central) - Feb 15, 2022
Data showed Aflibercept simultaneously affected these processes and determined the nominated axes that had been affected by the drug. Furthermore, integrating the results of Aflibercept on expression of candidate genes with the current network analysis suggested that resistance against the Aflibercept effect is a plausible process in HUVEC cells.
- | Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi
Journal: Fundus autofluorescence in the evaluation of diabetic macular edema treatment response. (Pubmed Central) - Feb 15, 2022
Furthermore, integrating the results of Aflibercept on expression of candidate genes with the current network analysis suggested that resistance against the Aflibercept effect is a plausible process in HUVEC cells. In DME, composite indices with baseline FAF predict variables such as BCVA in the follow-up of patients receiving ziv-AFL.
- |||| Clinical: Sharing & reminding colleagues I would’ve abandoned if no efficacy @FrontOncology Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) @BrownUCancer https://t.co/FOoVWrxmO3 (Twitter) - Feb 13, 2022
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept. (Pubmed Central) - Feb 12, 2022
Patients treated on average for 5.7 years, had a visual gain of 8.1 letters after 3 years and 6.6 letters after 4 years of IAI therapy. CMT significantly improved following the switch and was maintained.
- | Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Journal: Angiogenesis inhibitors: mechanism of action and nephrotoxicity (Pubmed Central) - Feb 11, 2022
The prescribing physician should be aware of these potentially serious. This article describes the mechanisms of action of antiangiogenic agents and their potential toxicities, with particular respect to the kidneys.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration. (Pubmed Central) - Feb 11, 2022
In a mouse laser-induced choroidal neovascularization (CNV) model, 4 × 10 genome copies of AAV8-nVEGFi exhibited a significantly increased reduction in the CNV area compared with AAV8-aflibercept (78.1% vs. 63.9%, p < 0.05), while causing no structural or functional changes to the retina. In conclusion, this preclinical study showed that subretinal injection of AAV8-nVEGFi was long lasting, well tolerated, and effective for nAMD treatment, supporting future translation to the clinic.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: OPTICAL COHERENCE TOMOGRAPHY FEATURES OF POLYPOIDAL LESION CLOSURE IN POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH AFLIBERCEPT. (Pubmed Central) - Feb 10, 2022
In conclusion, this preclinical study showed that subretinal injection of AAV8-nVEGFi was long lasting, well tolerated, and effective for nAMD treatment, supporting future translation to the clinic. PL closure, an important anatomical treatment outcome in PCV typically defined by ICGA, can be accurately detected by specific OCT features.